Statins therapy: A review on conventional and novel formulation approaches

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 8, 2011, Pages 983-998

  Tiwari, Radheshyam ^a   Pathak, Kamla ^a  

^a Rajiv Academy for Pharmacy ^*  (India)

Author keywords

Conventional drug delivery systems; Novel drug delivery systems; Statins

Indexed keywords

ATORVASTATIN; CYCLODEXTRIN; CYCLOSPORIN A; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOSOME; MACROGOL 6000; MEVINOLIN; NANOBEAD; OMEGA 3 FATTY ACID ESTER; POLYMER; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; SOLID LIPID NANOPARTICLE; STARSTAT; UNCLASSIFIED DRUG;

ACNE; AMINOTRANSFERASE BLOOD LEVEL; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CHOLESTEROL SYNTHESIS; DEVICE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG GRANULE; DRUG HALF LIFE; DRUG METABOLISM; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; FEMUR FRACTURE; GASTROINTESTINAL TRANSIT; HUMAN; HYDROGEL; HYPERCHOLESTEROLEMIA; KIDNEY FAILURE; LIVER DISEASE; LIVER FAILURE; LOW DRUG DOSE; MICROCAPSULE; MYOPATHY; NONHUMAN; PATIENT COMPLIANCE; PHARMACOLOGICAL PARAMETERS; POLYMERIZATION; PROTEINURIA; REPERFUSION INJURY; REVIEW; RHABDOMYOLYSIS; SELF EMULSIFYING DRUG DELIVERY SYSTEM; SELF NANOEMULSIFYING GRANULE; SIDE EFFECT; SINGLE DRUG DOSE; SOLID DISPERSION; SUSPENSION; TABLET DISINTEGRATION; TOXIC HEPATITIS; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIVER; TECHNOLOGY, PHARMACEUTICAL;

EID: 79959908456     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01273.x     Document Type: Review

References (101)

1. Nelson DL, Cox MM. Lehninger Principles of Biochemistry. New York: Macmillan, 2008.
2. Lazer HL. Role of statin therapy in the coronary bypass patient. Ann Thorac Surg 2009; 78: 730-740.
3. Roche VF. Antihyperlipidemic statins: a self-contained, clinically relevant medicinal chemistry lesson. Am J Pharm Edu 2005; 69: 546-560. (Pubitemid 41602665)
4. Bennett PN, Brown MJ. Clinical Pharmacology. London: Churchill Livingstone, 2003.
5. Endres M. Statins and stroke. J Cerebral Blood Flow Metabo 2005; 25: 1093-1110. (Pubitemid 41710736)
6. Bhatnagar D et al. Hypercholesterolaemia and management. BMJ 2008; 337: 993.
7. Tsompanidi EM et al. HDL biogenesis and functions: role of HDL quality and quantity in atherosclerosis. Atherosclerosis 2010; 208: 3-9.
8. Stalenhoef AFH. Management of mixed hyperlipidemia. Eur Heart J 2005; 26: 856-857.
9. Rang HP et al. Rang and Dale's Pharmacology. London: Churchill Livingstone, 2007.
10. Lardizable JA, Deedwania PC. The anti-ischemic and antianginal properties of statins. Curr Atheroscler Rep 2010; DOI: 10.1007/s11883-010-0147-y.
11. Villalobos ME et al. Similarities, differences and agonisms of pleiotropic effects of statins and omega-3 fatty acids. Nutr Hosp 2010; 25: 889-909.
12. DeKosky ST. Statin therapy in the treatment of Alzheimer disease: what is the rationale? Am J Med 2005; 118 (Suppl. 12A): 48-53.
13. Law MR et al. Quantifying effects of statins on low density lipoprotein cholesterol, ischemic heart disease and stroke: systemic review and met analysis. BMJ 2003; 326: 1423.
14. Xu J et al. Synergism of simvastatin with losartan prevents angiotensin II-induced cardiomyocyte apoptosis in vitro. J Pharm Pharmacol 2009; 61: 503-510.
15. Luo L et al. Hypercholesterolaemia induces early renal lesions characterized by upregulation of MMP-9 and iNOS and ETAR: alleviated by a dual endothelin receptor antagonist CPU0213 and simvastatin. J Pharm Pharmacol 2009; 61: 775-780.
16. Muck W. Clinical pharmacokinetics of cerivastatin. Clin Pharmacokinet 2000; 39: 99-116.
17. Siegel-Axel DI. Cerivastatin: a cellular and molecular drug for the future? Cell Mol Life Sci 2003; 60: 1144-1164.
18. Armitage J. The safety of statins in clinical practice. Lancet 2007; 370: 1781-1790. (Pubitemid 350137473)
19. Furberg CD, Pitt B. Withdrawl of cerivastatin from world market. Curr Control Trials Cardiovasc Med 2001; 2: 205-207.
20. Staffa JA et al. Cerivastatin and reports of fatal rhabdomylosis. N Engl J Med 2002; 346: 539-540.
21. Matzno S et al. Synergistic action of statins and nitrogen-containing bisphosphonates in the development of rhabdomyolysis in L6 rat skeletal myoblasts. J Pharm Pharmacol 2009; 61: 781-788.
22. White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 2002; 42: 963-970. (Pubitemid 34920793)
23. Pfefferkorn JA et al. Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors. Bioorg Med Chem Lett 2007; 17: 4538-4544. (Pubitemid 47058950)
24. Vandebist F et al. Inventors; Oral pharmaceutical composition containing a statin derivative United States patent US 20040235935. 2004 Nov 25.
25. Ballantyne CM et al. Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis. Clin Ther 2001; 23: 177-192.
26. Patel R, Patel M. Preparation, characterization, and dissolution behavior of a solid dispersion of simvastatin with polyethylene glycol 4000 and polyvinylpyrrolidone K30. J Disper Sci Tech 2008; 29: 193-194.
27. Suresh G et al. Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles. AAPS PharmSciTech 2007; 8: E1-E9.
28. 3 full-factorial design. AAPS PharmSciTech 2010; 11: 489-496.
29. Shah M et al. Oral solid Compitrol 888 ATO nanosuspension of simvastatin: optimization and biodistribution studies. Drug Dev Ind Pharm. posted online 3 Dec 2010; doi:10.3109/03639045.2010.527983 (epub ahead of print).
30. Lai J et al. Glyceryl monooleate/poloxamer 407 cubic nanoparticles as oral drug delivery systems: I. In vitro evaluation and enhanced oral bioavailability of the poorly water-soluble drug simvastatin. AAPS PharmSciTech 2009; 10: 960-966.
31. Ismail FA. Design and in vitro evaluation of polymeric formulae of simvastatin for local bone induction. Drug Dev Ind Pharm 2006; 32: 1199-1106.
32. Thylin MR et al. Effects of simvastatin gels on murine calvarial bone. J Periodontol 2002; 73: 1141-1148. (Pubitemid 35256265)
33. Morris S et al. Injectable simvastatin in periodontal defects and alveolar ridges: pilot studies. J Periodontol 2009; 79: 1465-1473.
34. Egashira K. Inventor; Pharmaceutical composition containing statin encapsulated nanoparticle. United States patent US 20100086602. 2010 Apr 8.
35. Garrett IR et al. Locally delivered lovastatin nanoparticles enhance fracture healing in rats. J Orthop Res 2007; 25: 1351-1357. (Pubitemid 47523365)
36. Benoit DS et al. Synthesis and characterization of a fluvastatin- releasing hydrogel delivery system to modulate hMSC differentiation and function for bone regeneration. Biomaterials 2006; 36: 6102-6110. (Pubitemid 44414974)
37. Jeon JH et al. Bioerodible devices for intermittent release of simvastatin acid. Int J Pharm 2007; 340: 6-12. (Pubitemid 47043348)
38. Lovich MA et al. Arterial heparin deposition: role of diffusion, convection and extravascular space. Am J Physiol Heart Circ Physiol 1998; 275: 2236-2242.
39. Jang GD. Inventor; Intravascular stent. United States patent US 6152957. 2000; Nov 28.
40. Pathak D et al. Solid dispersion of meloxicam: factorially designed dosage form for geriatric population. Acta Pharm 2008; 58: 99-110. (Pubitemid 351415844)
41. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 2000; 50: 47-60. (Pubitemid 30326688)
42. Vasconcelos T. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today 2007; 12: 1068-1075. (Pubitemid 350186132)
43. Silva TD et al. Preparation and characterization of solid dispersion of simvastatin. Drug Dev Ind Pharm 2010; 36: 1348-1355.
44. Loftsson T, Duchene D. Cyclodextrins and their pharmaceutical applications. Int J Pharm 2007; 329: 1-11. (Pubitemid 44937538)
45. Uekama K. Design and evaluation of cyclodextrin based drug formulation. Chem Pharm Bull 2004; 52: 900-915. (Pubitemid 41701863)
46. Manca ML et al. Diclofenac-b-cyclodextrin binary systems: physicochemical characterization and in vitro dissolution and diffusion studies. AAPS PharmSciTech 2005; 6: 464-472.
47. Stella VJ et al. Mechanisms of drug release from cyclodextrin complexes. Adv Drug Deliv Rev 1999; 36: 3-16. (Pubitemid 29074473)
48. Sami F et al. Effects of auxiliary substances on complexation efficiency and intrinsic dissolution rate of gemfibrozil-beta-CD complexes. AAPS PharmSciTech 2010; 11: 27-35.
49. Yoshinari M et al. Controlled release of simvastatin acid using cyclodextrin inclusion system. Dent Mater J 2007; 26: 451-456.
50. Lachman L et al. The Theory and Practice of Industrial Pharmacy. Bombay: Varghese Publishing House, 1991.
51. Venkataram S et al. inventors; HMG CoA reductase inhibiting composition, method for competitively inhibiting HMG CoA reductase using such composition. United States patent US 20030162827. 2003 Aug 28.
52. Gujman H et al. inventors; Novel statin pharmaceutical compositions and related methods of treatment. United States patent US 20060034815. 2006 Feb 16.
53. Carminati P, Duena AP. inventors; Pharmaceutical composition comprising microcapsules of statins suspended in alkyl esters of poly unsaturated fatty acids (PUFA). United States patent US 20090196920. 2009 Aug 6.
54. Patel PA et al. Self emulsifying drug delivery system: a review. Res J Pharm Technol 2008; 1: 313-323.
55. Reiss H. Entropy-induced dispersion of bulk liquids. J Colloid Interface Sci 1975; 53: 61-70.
56. Shen H, Zhong M. Preparation and evaluation of self-microemulsifying drug delivery systems (SMEDDS) containing atorvastatin. J Pharm Pharmacol 2006; 58: 1183-1191. (Pubitemid 44329099)
57. Gao P. Enhanced oral bioavailability of a poorly water soluble drug PNU- 91325 by supersaturable formulations. Drug Dev Ind Pharm 2004; 30: 221-229. (Pubitemid 38420267)
58. Kang BK et al. Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int J Pharm 2004; 274: 65-73. (Pubitemid 38457007)
59. Singla N et al. Oral bioavailability of simvastatin novel formulation in albino rats. J Pharm Sci Techol 2009; 1: 84-87.
60. Patil P et al. Formulation of a self-emulsifying system for oral delivery of simvastatin: in vitro and in vivo evaluation. Acta Pharm 2007; 57: 111-122. (Pubitemid 46361952)
61. Singh SK et al. Development and characterization of a lovastatin-loaded self-microemulsifying drug delivery system. Pharm Dev Technol 2009; 14: S1097-S9867.
62. Fahr A, Liu X. Drug delivery strategies for poorly water-soluble drugs. Expert Opin Drug Deliv 2007; 4: 403-416. (Pubitemid 47249138)
63. Dixit RP, Nagarsenker MS. Formulation and in vivo evaluation of self-nanoemulsifying granules for oral delivery of a combination of ezetimibe and simvastatin. Drug Dev Ind Pharm 2008; 34: 1285-1296.
64. Yuk SH et al. pH-sensitive drug delivery system using o/w emulsion. J Control Release 1995; 37: 69-74.
65. Lee KE et al. Microencapsulation of lipid nanoparticles containing lipophilic drug. J Microencapsul 2003; 20: 489-496. (Pubitemid 36805895)
66. Jenning V et al. Vitamin A-loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur J Pharm Biopharm 2000; 49: 211-218. (Pubitemid 30229868)
67. Cavalli R et al. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm 2002; 238: 241-245. (Pubitemid 34457892)
68. Uner M et al. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for application of ascorbyl palmitate. Pharmazie 2005; 60: 577-582. (Pubitemid 41153420)
69. Cavalli R et al. Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles. Int J Pharm 1997; 148: 47-54. (Pubitemid 27152216)
70. Shahgaldian P et al. Para-acyl-calix-arene based solid lipid nanoparticles (SLNs): a detailed study of preparation and stability parameters. Int J Pharm 2003; 253: 23-38. (Pubitemid 36197828)
71. Quintanar-Guerrero D et al. Adaptation and optimization of the emulsification-diffusion technique to prepare lipidic nanospheres. Eur J Pharm Sci 2005; 26: 211-218. (Pubitemid 41169804)
72. Schubert MA, Muller-Goyman CC. Solvent injection as a new approach for manufacturing lipid nanoparticles-evaluation of the method and process parameters. Eur J Pharm Biopharm 2003; 55: 125-131. (Pubitemid 36120504)
73. Krzic M et al. Improved skin oxygenation after benzyl nicotinate application in different carriers as measured by EPR oximetry in vivo. J Control Release 2001; 70: 203-211. (Pubitemid 32144804)
74. Song C, Liu S. A new healthy sunscreen system for human: solid lipid nanoparticles as carrier for 3, 4, 5-trimethoxybenzoylchitin and the improvement by adding Vitamin E. Int J Biol Macromol 2005; 36: 116-119. (Pubitemid 40966964)
75. Charcosset C et al. Preparation of solid lipid nanoparticles using a membrane contactor. J Control Release 2005; 108: 112-120. (Pubitemid 41476679)
76. Muller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs - a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol 2004; 113: 151-170. (Pubitemid 39237077)
77. Muller RH et al. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000; 50: 161-177. (Pubitemid 30326695)
78. Muller RH et al. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 2002; 242: 121-128.
79. Chen CC et al. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. Eur J Pharm Biopharm 2010; 74: 474-482.
80. Bhatti S et al. Preparation of tablets rapidly disintegrating in saliva containing bitter taste-masked granules by compression method. Ind J Pharm Sci 2007; 69: 80-84.
81. Sharma V et al. Modified polysaccharides as fast disintegrating excipients for orodispersible tablets of roxithromycin. AAPS PharmSciTech 2008; 9: 87-94.
82. Jansen KA. Inventor; Orally disintegratable simvastatin tablets, United States patent US 20070087050. 2007 Apr 19.
83. Butler J et al. Inventors; Pharmaceutical formulations and methods for modified release of statin drugs. United States patent US 20040132802. 2004 Jul 8.
84. Demierre M-F et al. Statins and cancer prevention. Nat Rev Cancer 2005; 5: 930-942. (Pubitemid 41766782)
85. Punitha S, Girish Y. Polymers in mucoadhesive buccal drug delivery system - a review. Int J Res Pharm Sci 2010; 1: 170-186.
86. Shidhaye SS et al. Buccal drug delivery of pravastatin sodium. AAPS PharmSciTech 2010; 11: 416-424.
87. Pradeep AR, Thorat MS. Clinical effect of subgingivally delivered simvastatin in the treatment of patients with chronic periodontitis: a randomized clinical trial. J Periodontol 2010; 81: 214-222.
88. Laufs U et al. Upregulation of endothelial nitric oxide synthase by HMG CoAreductase inhibitors. Circulation 1998; 97: 1129-1135. (Pubitemid 28152885)
89. Kureishi Y et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 6: 1004-1010.
90. Ranade VV, Holinger MA. Drug Delivery. NewYork, FL: CRC Press, 2004.
91. Lane EM. inventor; Fairfield Clinical Trials LLC., assignee. Transdemal delivery system for statin combination therapy. United States patent US 20050281868. 2005 Dec 22.
92. Benson HAE. Transdermal drug delivery: penetration enhancement techniques. Curr Drug Deliv 2005; 2: 23-33. (Pubitemid 40590918)
93. Yie H et al. inventors; Pficker Pharmaceuticals Ltd., assignee. Sustained-release preparation of statin drug. United States patent US 20090196910. 2009; Aug 6.
94. Lee Y et al. The effect of local simvastatin delivery strategies on mandibular bone formation in vivo. Biomaterials 2008; 29: 1940-1949.
95. Fresta M et al. 5-Fluorouracil - various kinds of loaded liposomes- encapsulation efficiency, storage stability and fusogenic properties. Int J Pharm 1993; 99: 145-156. (Pubitemid 23312030)
96. Prinz VP et al. Intravenous rosuvastatin for acute stroke treatment. Stroke 2008; 39: 433-438.
97. Kanjickal D et al. Polymeric sustained local drug delivery system for the prevention of vascular intimal hyperplasia. J Biomed Mater Res 2004; 68A: 489-495. (Pubitemid 38250369)
98. Vishwanathan A. A thesis on in vitro characterization of simvastatin loaded microspheres in the PolyRing device. 2008; 1-79.
99. Salvati A et al. Plum-pudding gels as a platform for drug delivery: understanding the effects of the different components on the diffusion behavior of solutes. J Phys Chem B Mater Surf Interfaces Biophys 2007; 111: 7367-7376. (Pubitemid 47152525)
100. Lynch I, Dawson KA. Release of model compounds from plumpudding- type gels composed of microgel particles randomly dispersed in a gel matrix. J Phys Chem B Mater Surf Interfaces Biophys 2004; 108: 19893-19898.
101. McGillicuddy FC et al. Novel plum pudding gels as potential drug-eluting stent coatings: controlled release of fluvastatin. J Biomed Mater Res A 2006; 79: 923-933. (Pubitemid 44915913)